Biogen vote ends in new squabble

The shareholder votes have been cast but don't expect either Carl Icahn or the executive team at Biogen Idec to agree anytime soon on the outcome of their bitter fight for control of the biotech giant. The meeting broke up with both sides squabbling over the results and an unexpected recess called during the vote counting. Icahn, who owns slightly more than 5 percent of the company, was proposing two dissident board members to push his plans to split the company in two. Report l Report

Suggested Articles

Seven years after regaining the fibrosis drug it had licensed out to Stromedix, Biogen is pulling the plug on a phase 2 study.

Smaller biotechs are continuing their biopharma hiring spree as two startups nab some big names for their aspiring cancer drug research.

In a 7-2 vote, an FDA panel backed Aimmune’s peanut allergy treatment for approval. It desensitizes patients with increasing doses of peanut protein.